Stocks · News reference
Hemab reports new HMB-002 Von Willebrand disease data, and introduced HMB-003, targeting heavy menstrual bleeding.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Shares of Webuy Global Ltd (NASDAQ:WBUY) rose sharply in pre-market trading. Webuy reported record preliminary unaudited travel bookings of around $4.76 million during the three-day NATAS Fair in Aug. 2026,
Read original at benzingaWedbush analyst David Nierengarten maintains Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Outperform and raises the price target from $55 to $64.
Read original at benzingaHC Wainwright & Co. analyst Emily Bodnar maintains Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Buy and raises the price target from $52 to $60.
Read original at benzingaFiled: 2026-08-11 AccNo: 0001193125-26-343421 Size: 251 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar